Ariad Pharmaceuticals Inc fka ARIA

[AmpleKind]

on May 15, we'll know most of the GIST, '113 impact....
Post ASCO, there is a dearth of trial news from Ariad for over a year until latter 2015.

But, if the GIST and 113 data is promising, then I'll be pretty
satisfied that it's just a question of time for a very significant
increase in Arad's value.

BTW, Dr.Gottlieb's article also notes that setbacks in biotech are
not at all unusual, and that often, companies do better subsequently.